Androgen Deprivation Therapy Market Report 2025

The androgen deprivation therapy market size has grown strongly in recent years. It will grow from $7.81 billion in 2024 to $8.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be linked to the increasing global incidence of prostate cancer, an expanding aging male population, a high rate of cancer recurrence, enhanced survival rates promoting prolonged treatment, and heightened awareness of early prostate cancer screening.

The androgen deprivation therapy market size is expected to see strong growth in the next few years. It will grow to $10.49 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth expected in the forecast period is driven by greater use of combination therapies in cancer treatment, a rising number of hormone-sensitive cancer cases, increased diagnosis of both localized and advanced prostate cancer, broader application of ADT for hormonal conditions beyond oncology, and a growing patient preference for non-invasive treatments. Key trends during this time include improvements in depot formulations and delivery systems, the development of oral ADT medications, the introduction of long-acting injectable ADT, the emergence of new androgen receptor inhibitors, and technological progress in digital pathology and diagnostic tools.

The rising number of prostate cancer cases is expected to drive the growth of the androgen deprivation therapy market in the coming years. Prostate cancer starts in the prostate gland, which is part of the male reproductive system and produces seminal fluid. The increase in cases is primarily due to longer lifespans, as aging significantly raises the risk of developing this cancer. Androgen deprivation therapy (ADT) is a key treatment option that works by reducing androgen levels, which fuel tumor growth. It is commonly used in advanced or metastatic prostate cancer to slow disease progression. For example, in January 2025, Prostate Cancer UK reported that prostate cancer diagnoses in England rose from 50,751 cases in 2022 to 55,033 cases in 2023, showing a noticeable increase in annual incidence. Therefore, the growing number of prostate cancer cases is boosting the androgen deprivation therapy market.

Leading companies in the androgen deprivation therapy market are focused on developing advanced treatments, including combination therapies, to improve outcomes in advanced prostate cancer. Combination therapy uses multiple treatments, such as hormone therapy alongside chemotherapy, to increase effectiveness and delay disease progression. For instance, in August 2022, Bayer AG received approval from the U.S. Food and Drug Administration for darolutamide combined with docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC). This newly approved combination therapy aims to improve survival rates and delay disease advancement in patients whose cancer has spread but still responds to hormone therapy. Darolutamide, an oral drug, uniquely binds tightly to androgen receptors, blocking their activity and helping to inhibit prostate cancer cell growth and spread.

In February 2025, Tempus, a U.S.-based health technology company, partnered with Artera to introduce ArteraAI Prostate Test, an advanced prostate cancer risk assessment tool. This collaboration uses artificial intelligence to improve cancer prognosis accuracy and support better medical decision-making. The ArteraAI digital pathology test, recognized in the NCCN guidelines, helps identify patients with intermediate localized prostate cancer who are more likely to benefit from short-term androgen deprivation therapy. Artera is a U.S.-based digital health company.

Major players in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy's Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., and Lawley Pharmaceuticals Pty Ltd.

North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in androgen deprivation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the androgen deprivation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The androgen deprivation therapy market consists of revenues earned by entities by providing services such as hormonal assessment, monitoring services, telehealth consultations, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The androgen deprivation therapy market also includes sales of hormone monitoring test kits, implantable hormone delivery systems, topical hormone regulation products, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The androgen deprivation therapy market research report is one of a series of new reports that provides androgen deprivation therapy market statistics, including androgen deprivation therapy industry global market size, regional shares, competitors with a androgen deprivation therapy market share, detailed androgen deprivation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the androgen deprivation therapy industry. This androgen deprivation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Androgen deprivation therapy is a treatment approach aimed at lowering or inhibiting the activity of male hormones in the body to restrict the growth of hormone-dependent cells. These hormones are vital for many physiological functions, and reducing their levels can have a significant impact on cellular behavior and biological processes.

The primary forms of androgen deprivation therapy include medication, surgery, and other methods. Medication-based ADT uses drugs to decrease or block androgen production. These drugs can be administered through various methods, such as injections or oral intake, and are prescribed to different patient groups, including men aged 40-60, 61-75, and those over 75. This therapy is primarily applied in the treatment of prostate cancer and other conditions, and is utilized by healthcare providers such as hospitals and specialty clinics.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.